Systems and methods for cancer prognosis

• Main Authors: SALMANS MICHAEL, YAO JOY, VIJAYARAGHAVAN, RAJ, ALEX SO, GOLKARAM MAHDI, ZHANG SHILE, WISE AARON, LIU LI, KAPLAN SHANNON
• Format: Patent
• Language: Chinese; English
• Published: 23.01.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; VINEGAR; WINE

The present invention provides a potential prognostic biomarker based on a combination of a composite score generated by sequence analysis of global human endogenous retrovirus (hERV)/retrotransposon transactivation and cell characteristics generated using deconvolution of immune cells within a tumor sample, to predict efficacy of chemotherapeutic agents and immune checkpoint inhibitors. The correlation analysis of the composite score with cellular characteristics within a tumor sample enables survival analysis in individuals receiving chemotherapeutic agents and immune checkpoint inhibitors. 本发明提供了一种潜在预后生物标志物，其是基于通过对全球人类内源性逆转录病毒(hERV)/逆转录转座子反式活化进行序列分析产生的复合评分和使用对肿瘤样品内免疫细胞进行的去卷积产生的细胞特征的组合，以预测化学治疗剂和免疫检查点抑制剂的功效。该复合评分与肿瘤样品内的细胞特征的相关分析能够在接受化学治疗剂和免疫检查点抑制剂的个体中进行存活分析。